More systematic studies comparing the impact of different radiation sources in well-defined tumour (and normal) models are therefore needed to understand the potential for Chk1 or Wee1 inhibitors to be utilised in order to optimise tumour radiosensitisation to the various radiation modalities. The gene discussed is CHEK1; the disease is neoplasm.